OBJECTIVE: This study reports the preliminary experience of dual grafts living donor liver transplantation (LDLT) for patients with acute-on-chronic liver failure (AoCLF) caused by hepatitis B. METHODS: Two patients who demonstrated acute-on-chronic hepatitis B liver failure and portal hypertension with Model for End-Stage Liver Disease (MELD) scores of 42 and 37, respectively, underwent dual LDLT grafts including one right lobe without a middle hepatic vein and one left lobe because the graft-to-recipient body weight ratio of the right lobe grafts were 0.53% and 0.66%. The donors and the recipients have been followed for over 1 year. RESULTS: Mortality and operative complications were not observed in the donors or recipients. At present, the donors and recipients have returned to their daily routine. No prisoners or organs from prisoners were used to obtain these data. CONCLUSION: Dual LDLT grafts including one right lobe without the middle hepatic vein and one left lobe may be a possible therapeutic option for subjects with acute-on-chronic hepatitis B-induced liver failure.
OBJECTIVE: This study reports the preliminary experience of dual grafts living donor liver transplantation (LDLT) for patients with acute-on-chronic liver failure (AoCLF) caused by hepatitis B. METHODS: Two patients who demonstrated acute-on-chronic hepatitis B liver failure and portal hypertension with Model for End-Stage Liver Disease (MELD) scores of 42 and 37, respectively, underwent dual LDLT grafts including one right lobe without a middle hepatic vein and one left lobe because the graft-to-recipient body weight ratio of the right lobe grafts were 0.53% and 0.66%. The donors and the recipients have been followed for over 1 year. RESULTS: Mortality and operative complications were not observed in the donors or recipients. At present, the donors and recipients have returned to their daily routine. No prisoners or organs from prisoners were used to obtain these data. CONCLUSION: Dual LDLT grafts including one right lobe without the middle hepatic vein and one left lobe may be a possible therapeutic option for subjects with acute-on-chronic hepatitis B-induced liver failure.